In prostate cancer alone, TP53 mutations were over four times more prevalent in MSK-IMPACT (29%) than in TCGA (7%), consistent with prior observations linking TP53 mutations to more aggressive disease [37]. Here, TP53 is linked to prostate carcinoma.